09.12.2009 • News

Umicore and Solvias Enter Next Level of Collaboration

Catalyst manufacturing company Umicore and technology provider Solvias have entered a long-term cooperation allowing quid pro quo access to each company's respective asymmetric catalysis technologies. The terms of this cooperation allow both Umicore and Solvias to offer a customer friendly IP access, both for the ligands and for the metal-ligand complexes. Clients now have the choice of utilizing either in-situ ligand technologies or employing ready-to-use chiral metal-ligand complexes in their processes. Besides simplifying their process, by which Solvias and Umicore cooperate, the fast availability of industrial quantities of chiral complexes based on a wide array of above mentioned ligand families allows end users to optimize process economics due to reduced catalyst consumption.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Virtual Event

Outsourced Biomanufacturing
Strategic Outsourcing in Biopharmaceuticals

Outsourced Biomanufacturing

April 22, 2026 | Join biopharma professionals, CDMO leaders, and supply chain innovators for a virtual event exploring the future of outsourced biomanufacturing.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.